Use of cryoprecipitate

The component contains most of the factor VIII, fibrinogen, factor XIII, von Willebrand factor and fibronectin from fresh frozen plasma.

Cryoprecipitate is indicated for the treatment of fibrinogen deficiency or dysfibrinogenaemia when there is clinical bleeding, an invasive procedure, trauma or disseminated intravascular coagulation.
 

Contraindications

Do not use cryoprecipitate for the treatment of haemophilia, von Willebrand’s disease or deficiencies of factor XIII or fibronectin unless alternative therapies are unavailable.

For further details, consult the Clinical Practice Guidelines on the Use of Blood Components.(1)
 

Dosage

Volume depends on clinical situation, patient size and laboratory tests. A common dose for fibrinogen replacement is 30–40 mL cryoprecipitate for each 10 kg patient body weight.

Discuss with your Haematologist or a Blood Service Medical Officer.

For patients with specific factor deficiencies, always consider specific replacement therapy (eg, factor VIII for haemophilia A, rather than cryoprecipitate).
 

Reference
  1. National Health and Medical Research Council & Australasian Society of Blood Transfusion. Clinical Practice Guidelines on the Use of Blood Components. Commonwealth of Australia, October 2002.